AlainAlgaziMD

Oncology • San Francisco, CA

Assistant Professor, Medicine, University of California, San Francisco, School of

Join to view full profile

Dr. Algazi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Algazi's full profile

Already have an account?

Office
505 Parnassus Ave # M1286
Box 1270
San Francisco, CA 94143
Phone+1 415-476-0624
Is this information wrong?

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2007 - 2010
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2004 - 2007
David Geffen School of Medicine at UCLAClass of 2004

Certifications & Licensure

CA State Medical License 2006 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma Start of enrollment: 2012 Jun 09
Completed
Phase 1, Phase 2
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets Start of enrollment: 2013 Apr 01
Terminated
Phase 2
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Start of enrollment: 2013 May 01
Completed
Phase 2
Trametinib With GSK2141795 in BRAF Wild-type Melanoma Start of enrollment: 2013 Sep 10
Completed
Phase 2
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
Active, not recruiting
Phase 2
Trial of pIL-12/MK-3475 in Metastatic Melanoma Start of enrollment: 2015 Aug 17
Completed
Phase 2
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Start of enrollment: 2016 Jul 06
Active, not recruiting
Phase 2
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2019 Mar 08
Recruiting
Phase 2
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Algazi, A., Moon, J., Lao, C., Chmielowski, B., Kendra, K., Lewis, K., Gonzalez, R., Kim, K., Godwin, J., Curti, B., Latkovic-Taber, M., Lomeli, S., Gufford, B., Scump...> ;Cancer. 2024 Jan 23
Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck.
Audrey Humphries, Connie J Zhou, Madeleine Welsh, Hyunseok Kang, Alain P Algazi, Lem, M.> ;Head & Neck. 2024 Feb 1
The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembrolizumab.
Angeline Truong, Xin Wu, Hyunseok Kang, Alain P Algazi, Ivan H El-Sayed, Jonathan R George, Chase M Heaton, William R Ryan, Patrick K Ha, Katherine C Wai, Lee, R.> ;Head & Neck. 2024 Jan 1
Treatment Modality Impact on Patient-Reported Quality of Life in Human Papilloma Virus-Associated Oropharyngeal Carcinoma.
Karolina A Plonowska-Hirschfeld, Arushi Gulati, Edgar Ochoa, Mary Jue Xu, Patrick K Ha, Chase M Heaton, Sue S Yom, Jason W Chan, Alain Algazi, Hyunseok Kang, William R...> ;The Laryngoscope. 2024 Apr 1
A prospective evaluation of neck and shoulder function following treatments of early-stage human papillomavirus-associated oropharynx cancer.
Arushi Gulati, Karolina Plonowska-Hirschfeld, Sagar Kansara, Edgar Ochoa, Mary J Xu, Patrick K Ha, Chase M Heaton, Sue S Yom, Jason W Chan, Alain P Algazi, Hyunseok Ka...> ;Clinical Otolaryngology. 2023 Sep 1
61 citations
Dynamic CD8T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.
Maha K Rahim, Trine Line H Okholm, Kyle B Jones, Elizabeth E McCarthy, Candace C Liu, Jacqueline L Yee, Stanley J Tamaki, Diana M Marquez, Iliana Tenvooren, Katherine ...> ;Cell. 2023 Mar 16
4 citations
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.
Do-Youn Oh, Alain Algazi, Jaume Capdevila, Federico Longo, Wilson Miller Jr, Jerry Tan Chun Bing, Carlos Eduardo Bonilla, Hyun Cheol Chung, Tormod K Guren, Chia-Chi Li...> ;Cancer. 2023 Apr 15
17 citations
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III...
A T C Chan, V H F Lee, R-L Hong, M-J Ahn, W Q Chong, S-B Kim, G F Ho, P B Caguioa, N Ngamphaiboon, C Ho, M A S A Aziz, Q S Ng, C-J Yen, N Soparattanapaisarn, R K-C Nga...> ;Annals of Oncology. 2023 Mar 1
5 citations
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Charu Aggarwal, Nabil F Saba, Alain Algazi, Ammar Sukari, Tanguy Y Seiwert, Missak Haigentz, Mercedes Porosnicu, Marcelo Bonomi, Jean Boyer, Mark T Esser, Lily I Cheng...> ;Clinical Cancer Research. 2023 Feb 1
5 citations
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.
Aung Naing, Alain P Algazi, Gerald S Falchook, Benjamin C Creelan, John Powderly, Seth Rosen, Minal Barve, Niharika B Mettu, Pierre L Triozzi, John Hamm, Gongfu Zhou, ...> ;Cancer. 2023 Jan 1
Melanoma risk during immunomodulating treatment.
Yixuan James Zheng, Wilson Ho, Martina Sanlorenzo, Igor Vujic, Adil Daud, Alain Algazi, Klemens Rappersberger, Susana Ortiz-Urda> ;Melanoma Research. 2022 Dec 1
2 citations
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINA...
Hani Babiker, Erkut Borazanci, Vivek Subbiah, Sanjiv Agarwala, Alain Algazi, Jacob Schachter, Michael Lotem, Corinne Maurice-Dror, Daniel Hendler, Shah Rahimian, Hans ...> ;Clinical Cancer Research. 2022 Dec 1
4 citations
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.
Jack Y Lee, Bianca Nguyen, Anandaroop Mukhopadhyay, Mia Han, Jun Zhang, Ravindra Gujar, Jon Salazar, Reneta Hermiz, Lauren Svenson, Erica Browning, H Kim Lyerly, David...> ;Molecular Therapy Oncolytics. 2022 Jun 16
6 citations
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity.
Mia Han, Bianca Nguyen, Jack Y Lee, Erica Browning, Jun Zhang, Anandaroop Mukhopadhyay, Ravindra Gujar, Jon Salazar, Reneta Hermiz, Lauren Svenson, Annah S Rolig, Will...> ;Molecular Cancer Research. 2022 Jun 3
10 citations
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
Cohen, E., Nabell, L., Wong, D., Day, T., Daniels, G., Milhem, M., Deva, S., Jameson, M., Guntinas-Lichius, O., Almubarak, M., Strother, M., Whitman, E., Chisamore, M....> ;Clinical Cancer Research. 2022 Mar 15
12 citations
Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Matthew H. Taylor, Courtney Betts, Lauren Maloney, Eric Nadler, Alain Algazi, Michael J. Guarino, John Nemunaitis, Antonio Jimeno, Priti Patel, Veerendra Munugalavadla...> ;Clinical Cancer Research. 2021 Dec 3
98 citations
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label...
Hussein Abdul-Hassan Tawbi, Peter A. Forsyth, F. Stephen Hodi, Alain Algazi, Omid Hamid, Christopher D. Lao, Stergios J. Moschos, Michael B. Atkins, Karl D. Lewis, Mic...> ;The Lancet. Oncology. 2021 Nov 10
63 citations
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Yujue Wang, Sixue Liu, Zhentao Yang, Alain Algazi, Shirley H. Lomeli, Yan Wang, Megan Othus, Aayoung Hong, Xiaoyan Wang, Chris E. Randolph, Alexis Jones, Marcus Bosenb...> ;Cancer Cell. 2021 Oct 11
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael D. Gordon, Leonel Hernandez-Aya, Donald P. Lawrence, Jose Lutzky, Wilson H....> ;Nature Communications. 2021 Aug 12
54 citations
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
Hussein Abdul-Hassan Tawbi, Peter A. Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid, Michael B. Atkins, Karl D. Lewis, Reena Thomas, Joh...> ;Neuro-Oncology. 2021 Apr 21
183 citations
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomi...
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, M...> ;The Lancet. Oncology. 2021 May 1
32 citations
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomise...
Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Mesh...> ;The Lancet. Oncology. 2021 May 1
42 citations
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael D. Gordon, Leonel Hernandez-Aya, Donald P. Lawrence, Jose Lutzky, Wilson H....> ;Nature Communications. 2020 Dec 7
65 citations
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert, Thach Giao Truong, Robert M. Conry, Kari Kendra, Gary C. Doolittle, Joseph I. Clark, Michael J. M...> ;Nature Medicine. 2020 Oct 5
7 citations
Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma
Lauren S. Levine, Kelly M. Mahuron, Katy K. Tsai, Clinton Wu, Daiva M. Mattis, Mariela L. Pauli, Arielle Oglesby, James Lee, Matthew H. Spitzer, Matthew F. Krummel, Al...> ;Annals of Surgical Oncology. 2020 Jun 2
Join now to see all

Journal Articles

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Kim Margolin, Alain Algazi, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igo..., The New England Journal of Medicine

Press Mentions

Leaving Lymph Nodes Intact Could Increase Efficacy of Cancer ImmunotherapyApril 12th, 2023
Sequential-Combinatorial Regimens Can Make Treatment More Effective for People with Aggressive CancersAugust 12th, 2021
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and NeckMay 19th, 2021
Join now to see all